Anti-IgE monoclonal antibody for the treatment of asthma and other manifestations related to allergic diseases

Jornal de Pediatria

Volumn 82, Issue SUPPL. 2, 2006, Pages

  Sarinho, Emanuel ^a,c   Cruz, Álvaro Augusto ^b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c NONE   (Brazil)

Author keywords

Allergic rhinitis; Anti IgE; Asthma; Atopic dermatitis; Omalizumab; Severe asthma

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ASTHMA; BRONCHOSPASM; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; ERYTHEMA; FOOD ALLERGY; HEADACHE; HELMINTHIASIS; HUMAN; HYPERSENSITIVITY REACTION; MEDLINE; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; PARASITOSIS; PARESTHESIA; PHARYNGITIS; PHOTOSENSITIZATION; PRURITUS; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; WEIGHT GAIN;

ADULT; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BODY WEIGHT; CHILD; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33845777191     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1551     Document Type: Review

References (54)

1. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459-65.
2. Infuhr D, Crameri R, Lamers R, Achatz G. Molecular and cellular targets of anti-IgE antibodies. Allergy. 2005;60:977-85.
3. Cooper PJ. Intestinal worms and human allergy. Parasite Immunol. 2004;26:455-67.
4. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites and the hygiene hypothesis. Science. 2002;296:490-4
5. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005; 35:408-16.
6. Corry DB, Kheradmand F. Control of allergic airway inflammation through immunomodulation. J Allergy Clin Immunol. 2006;117(2 Suppl Mini-Primer):S461-4.
7. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-90.
8. Berger WE. What is new in antiimmunoglobulin E asthma therapy. Allergy Asthma Proc. 2005;26:428-34.
9. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;354: 2689-95.
10. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19:491-8.
11. Soresi S, Togias A. Mechanisms of action of anti-immunoglobulin E therapy. Allergy Asthma Proc. 2006;27(2 Suppl 1):S15-23.
12. Brownell J, Casale TB. Anti-IgE therapy. Immunol Allergy Clin North Am. 2004;24:551-68.
13. Marcus P; Practice Management Committee, American College of Chest Physicians Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest. 2006;129:466-74.
14. Wagelie-Steffen AL, Kavanaugh AF, Wasserman SI. Biologic therapies for the treatment of asthma. Clin Chest Med. 2006;27:133-47.
15. Clark J, Chiang D, Casale TB. Omalizumab in the treatment of allergic respiratory disease. J Asthma. 2006;43:87-93.
16. Huang YC, Leyko B, Frieri M. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann Allergy Asthma Immunol. 2005;95:443-51.
17. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy: (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309-16
18. Rolinck-Werninghaus C, Wahn U, Hamelmann E. Anti-IgE therapy in allergic asthma. current drug targets. Inflamm Allergy. 2005;4:551-64.
19. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:158-62.
20. Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. Med Gen Med. 2005;7:27.
21. Lanier BQ. Unanswered questions and warnings involving anti-immunoglobulin E therapy based on 2-year observation of clinical experience. Allergy Asthma Proc. 2005;26:435-9.
22. Clark J, Chiang D, Casale TB. Omalizumab in the treatment of allergic respiratory disease. J Asthma. 2006;43:87-93.
23. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, et al; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134-40.
24. Holgate ST, Holloway J, Wilson S, Howarth PH, Haitchi HM, Babu S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol. 2006;117:496-506.
25. Milgrom H, Fick RBJr, Su JQ, Reimann JD, Bush RK, Wautrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody rhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966-73.
26. Jonkers RE, van der Zee JS. Anti-IgE and other new immunomodulation-based therapies for allergic asthma. Neth J Med 2005;63:121-8.
27. Buhl R. Omalizumab (Xolair®) improves quality of life in adult patients with allergic asthma: a review. Respir Med. 2003;97:123-9
28. Soler M, Matz J, Townley R, Buhl H, O'Brien J, Fox H, et al. The IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-61.
29. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36.
30. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59:701-8.
31. Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J. 2002;20:1088-94.
32. Lemanske RF, Nayak A, McAlary M, Everhard F, Fowler-Taylor, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics. 2002;110:E55.
33. Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2003;111:278-84.
34. Niebauer K, Dewilde S, Fox-Rushby J, Revicki DA. Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2006;96:316-26.
35. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003;111:87-90.
36. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children (Cochrane Review). In: The Cochrane Library, Issue 4, 2004.
37. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125:1378-86.
38. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gestner B, et al The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004;59:973-9.
39. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol. 2002;110:68-71
40. Chervinsky P, Casale T, Townley R, Triphaty I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91:160-7.
41. Poole JA, Matangkasombut P, Rosenwasser LJ. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol. 2005;115:S376-85.
42. Hamelmann E, Rolinck-Werninghaus C, Wahn U. Is there a role for anti-IgE in combination with specific allergen immunotherapy? Curr Opin Allergy Clin Immunol. 2003;3:501-10.
43. Fiebiger E, Maurer D, Holub H, Reininger B, Hartmann G, Woisetschlager M, et al. Serum IgG antibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest. 1995;96:2006-12.
44. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006;54:68-72
45. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55:168-70
46. Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986-93
47. Shreffler WG, Beyer K, Chu TH, Burks AW, Sampson HA. Microarray immunoassay: association of clinical history, in vitro IgE function, and heterogeneity of allergenic peanut epitopes. J Allergy Clin Immunol. 2004;113:776-82.
48. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003;91:182-8.
49. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, Mc Alary M, at al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36.
50. Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics. 2004;113:e308-12.
51. Holgate ST, Chuchalin AG, Hebert J, Lötvall J, Persson GB, Chung KF, et al. Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632-8.
52. Holgate ST, Holloway J, Wilson S, Howarth PH, Haitchi HM, Babu S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol. 2006;117:496-506.
53. Cooper PJ, Lima F, Sarinho EC, Ayre G, Martin C, Fox H, Cruz AA. Safety of Anti-IgE Therapy with Omalizumabe in Allergic Patients at Risk of Geohelminth Infection. J Allergy Clin Immunol. 2006;117:S9.
54. Cruz AA. Asma, Um Grande Desafio. Rio de Janeiro: Atheneu; 2004.